TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00090779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: twice daily
Study: NCT02651376

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional plus AAIT
Description: Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3\*10E8 MNCs/kg body at baseline, week 1 and 2.
Study: NCT01165463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT basic training
Description: 10 hours of basic training
Study: NCT04078958

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salmon fishmeal
Description: Salmon fishmeal with high protein content
Study: NCT01165463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT basic training
Description: 10 hours of basic training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT basic training
Description: 10 hours of basic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Crossword Puzzles
Description: Subjects train with puzzles 10 hrs in lab.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOPT booster training
Description: 4 hours of subsequent booster-training
Study: NCT00777257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
Description: Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.
Description: Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
Study: NCT04078958

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey
Description: Whey with high protein content
Study: NCT04166175

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy
Description: lateral internal sphincterotomy under GA in lithotomy position
Study: NCT00795106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Study: NCT00777257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Description: Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
Study: NCT00795106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
Study: NCT03565744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B'N Fit POWER
Description: Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
Study: NCT03009981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRH Analogue
Description: Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Analogue
Description: Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.
Study: NCT02342691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLXA4
Description: BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral rinse
Description: The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
Study: NCT03009981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Analogue
Description: Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~1. Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~   OR:~2. Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
Study: NCT00738595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 302
Description: EVT 302 5 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EVT 302, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT 302 plus open label Nicotine replacement
Description: Double-blind EVT 302 plus open label nicotine replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus open label Nicotine Replacement
Description: Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
Study: NCT02108470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental consultation using OHIP
Description: The S-OHIP\[M\] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
Study: NCT01378949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5% with adrenaline 5 mcg/cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.5% with adrenaline 5 mcg/cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine 1 mg/cc
Study: NCT04360915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067
Description: Take ASK120067 tablets orally in first day at 160 mg in fast condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ASK120067 in fed condition
Description: Take ASK120067 tablets orally in first day at 160 mg in fed condition.
Study: NCT05609006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy, Low-Volume ONS
Description: 2 bottles/day of a High-Energy, Low-Volume ONS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy, Low-Volume ONS
Description: 2 bottles/day of a High-Energy, Low-Volume ONS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy Standard ONS
Description: 2 bottles/day of a High-Energy Standard ONS

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Energy Standard ONS
Description: 2 bottles/day of a High-Energy Standard ONS
Study: NCT03640130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze-contingent text enhancement
Description: In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight.
Study: NCT06393270

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified US Public Health Service (USPHS) criteria
Description: Dental caries classification system
Study: NCT03689478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermic intravesical chemotherapy
Description: Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
Study: NCT01050868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Combo Kit mg DE/de
Study: NCT03383198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine right injection
Description: Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine left injection
Description: Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
Study: NCT02498184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Study: NCT01488929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00666029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 40 m.g. o.d. tablets for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT01818921

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: ZGN-440 sterile diluent/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2 mg ZGN-440 for injectable suspension
Description: 1.2 mg beloranib
Study: NCT06393270

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified US Public Health Service (USPHS) criteria
Description: Dental caries classification system

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified US Public Health Service (USPHS) criteria
Description: Dental caries classification system
Study: NCT04904406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir / Lamivudine Oral Tablet
Description: Discontinuing abacavir by switching from three-drug regimen with dolutegravir/abacavir/lamivudine to two-drug regimen with dolutegravir/lamivudine
Study: NCT04145921

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS for MIS-THA
Description: enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional MIS-THA
Description: conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
Study: NCT02534025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemia preconditioining
Description: Elavate blood pressure cuff pressure to 200
Study: NCT01812213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]NAV4694
Study: NCT04579250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF0103-00-VP (H10ssF-6473)
Description: The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF0103-00-VP (H10ssF-6473)
Description: The vaccine is composed of the haemagglutinin (HA) stem domain from A/Jiangxi/IPB13/2013 (H10N8) influenza genetically fused to the ferritin protein from H. pylori. Purified H10ssF-6473 displays eight well-formed HA trimers that antigenically resemble the native H10 stem viral spikes.
Study: NCT02437422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE
Description: Single two-hour infusion of SANGUINATE
Study: NCT03769870

Intervention type: DRUG
Group type: OTHER
Intervention: Teneligliptin 20mg/day
Description: cross-over

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin 40mg/Day
Description: cross-over
Study: NCT04010656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVR-based self-catheterization
Description: Home self-catheterization based on standard of care
Study: NCT03133819

Intervention type: DEVICE
Group type: OTHER
Intervention: Q-Sense_QST (TSA II)
Description: QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
Study: NCT03594747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously as described

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously as described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously as described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously as described

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously as described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously as described
Study: NCT01818921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.8 mg ZGN-440 for injectable suspension
Description: 1.8 mg beloranib
Study: NCT03594747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously as described
Study: NCT02569476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Study: NCT01367002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin/Paclitaxel
Description: Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
Study: NCT03303924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514 and sulbactam
Description: Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
Study: NCT02847156

Intervention type: OTHER
Group type: OTHER
Intervention: Physical assessment
Description: 1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
Study: NCT01385566

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous
Description: One 0.65 mL injection subcutaneously on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous
Description: One approximately 0.22 mL injection subcutaneously on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal
Description: Two intradermal injections of approximately 0.15 mL each on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal
Description: One intradermal injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal
Description: One intradermal injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal
Description: One intradermal injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full Dose Intradermal Placebo
Description: Two intradermal placebo injections of approximately 0.15 mL each on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Placebo
Description: One intradermal placebo injection of approximately 0.1 mL on Day 1
Study: NCT04674930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Home based exercise program including aerobic and resistance training will be carried out for a period of 6 weeks. Duration of aerobic exercise will be starting at 20 min/session, and progress to 30 ruin/session, with an increased pace according to the patient's capabilities. Resistance training with thera-band for 1 set of 10 repetitions twice a week. One RM will be reassessed weekly, and the program will be adjusted accordingly.
Study: NCT01886495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutrition intervention
Study: NCT04126460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a type of PD-1 antibody
Study: NCT01963962

Intervention type: DRUG
Intervention: Copper IUD

Intervention type: DRUG
Intervention: Levonorgestrel IUD
Study: NCT01474889

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.